BACKGROUND: Antibodies directed against citrullinated proteins (eg anti-cyclic citrullinated peptide (CCP)) have excellent diagnostic and good prognostic potential for rheumatoid arthritis. Type 1 autoimmune hepatitis (AIH-1) is a chronic liver disease characterised by a variety of serum autoantibodies. Recently, in a large group of patients with AIH-1 without clear rheumatoid arthritis overlap, a relatively high percentage (9%) of anti-CCP2 positivity was scored. OBJECTIVES: To characterise the citrulline-dependence of the observed anti-CCP2 positivity in AIH-1 sera as well as in other groups of patients without rheumatoid arthritis (mainly rheumatic diseases). METHODS: Serum samples of 57 patients with AIH-1 and 66 patients without rheumatoid arthritis, most of them reported as anti-CCP positive, were tested for citrulline-specific reactivity with a second generation anti-CCP kit, with the citrullinated and the corresponding non-citrullinated (arginine-containing) antigen. A subset of AIH-1 sera was also tested with a CCP1 ELISA (and arginine control). RESULTS: The anti-CCP2 reactivity of most non-rheumatoid arthritis rheumatic diseases samples (87-93%) was citrulline-specific, whereas a relatively high percentage of AIH-1 samples (42-50%) turned out to be reactive in a citrulline-independent manner. The use of citrullinated and non-citrullinated CCP1 peptides confirmed a high occurrence of citrulline-independent reactivity in AIH-1 samples. CONCLUSIONS: In rheumatoid arthritis and most non-rheumatoid arthritis rheumatologic disease sera, anti-CCP positivity is citrulline-dependent. However in some patients, particularly patients with AIH-1, citrulline-independent reactivity in the anti-CCP2 test can occur. A positive CCP test in a non-rheumatic disease (eg liver disease) should therefore be interpreted with care, and preferably followed by a control ELISA with a non-citrullinated antigen.
BACKGROUND: Antibodies directed against citrullinated proteins (eg anti-cyclic citrullinated peptide (CCP)) have excellent diagnostic and good prognostic potential for rheumatoid arthritis. Type 1 autoimmune hepatitis (AIH-1) is a chronic liver disease characterised by a variety of serum autoantibodies. Recently, in a large group of patients with AIH-1 without clear rheumatoid arthritis overlap, a relatively high percentage (9%) of anti-CCP2 positivity was scored. OBJECTIVES: To characterise the citrulline-dependence of the observed anti-CCP2 positivity in AIH-1 sera as well as in other groups of patients without rheumatoid arthritis (mainly rheumatic diseases). METHODS: Serum samples of 57 patients with AIH-1 and 66 patients without rheumatoid arthritis, most of them reported as anti-CCP positive, were tested for citrulline-specific reactivity with a second generation anti-CCP kit, with the citrullinated and the corresponding non-citrullinated (arginine-containing) antigen. A subset of AIH-1 sera was also tested with a CCP1 ELISA (and arginine control). RESULTS: The anti-CCP2 reactivity of most non-rheumatoid arthritis rheumatic diseases samples (87-93%) was citrulline-specific, whereas a relatively high percentage of AIH-1 samples (42-50%) turned out to be reactive in a citrulline-independent manner. The use of citrullinated and non-citrullinatedCCP1 peptides confirmed a high occurrence of citrulline-independent reactivity in AIH-1 samples. CONCLUSIONS: In rheumatoid arthritis and most non-rheumatoid arthritis rheumatologic disease sera, anti-CCP positivity is citrulline-dependent. However in some patients, particularly patients with AIH-1, citrulline-independent reactivity in the anti-CCP2 test can occur. A positive CCP test in a non-rheumatic disease (eg liver disease) should therefore be interpreted with care, and preferably followed by a control ELISA with a non-citrullinated antigen.
Authors: J-E Gottenberg; S Mignot; P Nicaise-Rolland; J Cohen-Solal; F Aucouturier; J Goetz; C Labarre; O Meyer; J Sibilia; X Mariette Journal: Ann Rheum Dis Date: 2004-07-01 Impact factor: 19.103
Authors: Diego Vergani; Fernando Alvarez; Francesco B Bianchi; Eduardo L R Cançado; Ian R Mackay; Michael P Manns; Mikio Nishioka; Edward Penner Journal: J Hepatol Date: 2004-10 Impact factor: 25.083
Authors: I E A Hoffman; I Peene; L Cebecauer; D Isenberg; T W J Huizinga; A Union; L Meheus; K De Bosschere; F Hulstaert; E M Veys; F De Keyser Journal: Ann Rheum Dis Date: 2005-02 Impact factor: 19.103
Authors: M Fusconi; A Vannini; A C Dall'Aglio; G Pappas; F Cassani; G Ballardini; M Frisoni; A Grassi; F B Bianchi; D Zauli Journal: Aliment Pharmacol Ther Date: 2005-11-15 Impact factor: 8.171
Authors: Paula A Correa; Gabriel J Tobón; Gustavo Citera; José Cadena; Emilce Schneeberger; José F Camargo; José A Maldonado-Cocco; Juan Manuel Anaya Journal: Biomedica Date: 2004-06 Impact factor: 0.935
Authors: B Vander Cruyssen; I E A Hoffman; H Zmierczak; M Van den Berghe; E Kruithof; L De Rycke; H Mielants; E M Veys; D Baeten; F De Keyser Journal: Ann Rheum Dis Date: 2005-02-04 Impact factor: 19.103
Authors: Belén García-Berrocal; Concepción González; Marta Pérez; José A Navajo; Isabel Moreta; Carmen Dávila; José M González-Buitrago Journal: Clin Chim Acta Date: 2005-04 Impact factor: 3.786
Authors: Prasanthi Kakumanu; Eric S Sobel; Sonali Narain; Yi Li; Jun Akaogi; Yoshioki Yamasaki; Mark S Segal; Paulette C Hahn; Edward K L Chan; Westley H Reeves; Minoru Satoh Journal: J Rheumatol Date: 2009-11-02 Impact factor: 4.666
Authors: Ori Elkayam; Refael Segal; Daniele Bendayan; Robert van Uitert; Carla Onnekink; Ger Jm Pruijn Journal: Arthritis Res Ther Date: 2010-01-25 Impact factor: 5.156